Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay

Reuters

Aug 15

Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay

Caris Life Sciences Inc., a leading AI TechBio company in precision medicine, has announced the FDA approval of their MI Cancer Seek® assay. This pioneering diagnostic tool is designed to identify cancer patients who may benefit from targeted therapies and is unique in its combination of whole exome and whole transcriptome sequencing for solid tumor profiling in both adults and children. The assay supports eight companion diagnostic claims and demonstrates high performance and reliability. This advancement marks a significant step forward in precision oncology, enhancing the ability to provide personalized treatment options for cancer patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA52033) on August 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2559911443"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559911443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559911443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-15 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559911443","market":"nz","top_or_hot":-1,"title":"Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc., a leading AI TechBio company in precision medicine, has announced the FDA approval of their MI Cancer Seek® assay. This pioneering diagnostic tool is designed to identify cancer patients who may benefit from targeted therapies and is unique in its combination of whole exome and whole transcriptome sequencing for solid tumor profiling in both adults and children. The assay supports eight companion diagnostic claims and demonstrates high performance and reliability. This advancement marks a significant step forward in precision oncology, enhancing the ability to provide personalized treatment options for cancer patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA52033) on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-15 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc., a leading AI TechBio company in precision medicine, has announced the FDA approval of their MI Cancer Seek® assay. This pioneering diagnostic tool is designed to identify cancer patients who may benefit from targeted therapies and is unique in its combination of whole exome and whole transcriptome sequencing for solid tumor profiling in both adults and children. The assay supports eight companion diagnostic claims and demonstrates high performance and reliability. This advancement marks a significant step forward in precision oncology, enhancing the ability to provide personalized treatment options for cancer patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA52033) on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAI","symbol_name":"Caris Life Sciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL6QkbzK:1","article_id":"2559911443","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559911443","pubTimestamp":1755261057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Caris Life Sciences Inc., a leading AI TechBio company in precision medicine, has announced the FDA approval of their MI Cancer Seek assay. This pioneering diagnostic tool is designed to identify cancer patients who may benefit from targeted therapies and is unique in its combination of whole exome and whole transcriptome sequencing for solid tumor profiling in both adults and children. The assay supports eight companion diagnostic claims and demonstrates high performance and reliability. This advancement marks a significant step forward in precision oncology, enhancing the ability to provide personalized treatment options for cancer patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the origina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAI":"Caris Life Sciences, Inc.","BK4104":"贸易公司与经销商","BK4139":"生物科技"},"translate_title":"Caris Life Sciences获得FDA批准MI Cancer Seek®一种开创性的精确肿瘤学检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":0.9},"content_text":"Caris Life Sciences Secures FDA Approval for MI Cancer Seek®, a Pioneering Precision Oncology Assay\n    \n\n        Caris Life Sciences Inc., a leading AI TechBio company in precision medicine, has announced the FDA approval of their MI Cancer Seek® assay. This pioneering diagnostic tool is designed to identify cancer patients who may benefit from targeted therapies and is unique in its combination of whole exome and whole transcriptome sequencing for solid tumor profiling in both adults and children. The assay supports eight companion diagnostic claims and demonstrates high performance and reliability. This advancement marks a significant step forward in precision oncology, enhancing the ability to provide personalized treatment options for cancer patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA52033) on August 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}